Eli Lilly
Eli Lilly’s Trulicity approved in US to reduce cardiovascular events in type 2 diabetes patients
February 24, 2020Sales and Marketing Eli Lilly, Trulicity, cardiovascular disease, pharma
Eli Lilly’s Trulicity (duraglutide) has been awarded marketing authorisation from the FDA as a therapy to reduce major adverse cardiovascular …
Lilly and Incyte’s atopic dermatitis drug shows promise at Phase 3
February 13, 2020Sales and Marketing Eli Lilly, Incyte, baricitinib, pharma
Eli Lilly and Incyte have pulled back the curtain on Phase 3 data on their oral selective JAK inhibitor baricitinib …
Lilly & Incyte’s Olumiant hits main goal in atopic dermatitis
January 28, 2020Manufacturing and Production, Research and Development Eli Lilly, Olumiant, pharma
Eli Lilly and Incyte have lifted the curtain on new Phase 3 data showing that their oral JAK inhibitor, showing …
Eli Lilly to boost immunology portfolio with $1.1bn Dermira acquisition
January 13, 2020Sales and Marketing Dermira, Eli Lilly, pharma
Eli Lilly has announced it has entered into an agreement to acquire Dermira, a biopharmaceutical firm focused on the development …
FibroGen names Lilly veteran as new CEO
January 7, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, fibrogen, pharma
Eli Lilly veteran Enrique Conterno has been revealed as the new Chief Executive Officer of FibroGen following the unexpected death …
Eli Lilly CEO says Elizabeth Warren’s claims they failed on cheaper insulin is ‘nonsense’
December 18, 2019Research and Development Bernie Sanders, Eli Lilly, Elizabeth Warren, US Pharma, US Presidential Election, insulin
David Ricks, the CEO of Eli Lilly, has said that Presidential candidate Senator Elizabeth Warren’s claims his company failed on …
New ICER report reveals most cost-effective rheumatoid arthritis therapies
November 27, 2019Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma
The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …
Lilly to boost Indianapolis manufacturing site with $400m injection, 100 jobs to be created
November 20, 2019Manufacturing and Production, Research and Development Eli Lilly, US, pharma
Eli Lilly is poised to boost its manufacturing capacity with the investment of $400 million at its Lilly Technology Center …
FDA advisory committee votes down approval of Boehringer and Lilly’s drug for type 1 diabetes
November 14, 2019Sales and Marketing Boehringer Ingelheim, Eli Lilly, empagliflozin, jardiance, pharma
Boehringer Ingelheim and Eli Lilly’s have been dealt a blow from the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), …
Lilly’s pegilodecakin combo falls at Phase 3 in pancreatic cancer
October 17, 2019Research and Development Cancer, Eli Lilly, FOLFOX, Pancreatic cancer, pegilodecakin, pharma
In disappointing news, Eli Lilly has revealed that pegilodecakin, in combination with the chemotherapy regimen FOLFOX (Folinic acid, Fluorouracil and …
Lilly’s Reyvow becomes first FDA-approved 5-HT1F receptor agonist for acute migraine
October 15, 2019Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Reyvow, US, migraine, pharma
Eli Lilly has announced that the FDA has given the green light to Reyvow (lasmiditan) in the acute treatment of …
Lilly’s LOXO-292 shrinks tumours in lung cancer trial
September 9, 2019Research and Development, Sales and Marketing Cancer, Eli Lilly, lung cancer, pharma
Eli Lilly has announced its experimental cancer drug LOXO-292, acquired in January, shrank tumours in almost 70% of advanced lung …
Mylan gets provisional FDA greenlight for generic version of Lilly’s blockbuster cancer drug Alimta
September 2, 2019Sales and Marketing Alimta, Cancer, Eli Lilly, FDA, Mylan, pharma
Mylan has scored a preliminary approval in the US from the FDA for its generic version of Eli Lilly’s blockbuster …
Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis
August 15, 2019Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis
Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …
Top Ten most popular articles on Pharmafile.com this week!
August 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, CAR T, CAR-T, Eli Lilly, Lexicon, Medicare, Novartis, Pfizer, Sanofi, pharma
This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The …
Latest content
Five Facts about cardiovascular disease
